Analysis of cumulative live birth rate outcomes of four ovarian stimulation protocols in Poseidon groups 3/4 patients with adenomyosis

other OA: closed public-domain-us
AI-generated summary by claude@2026-06, 2026-06-07

In adenomyosis patients with poor ovarian response (Poseidon groups 3/4), the GnRH agonist protocol demonstrated a higher cumulative live birth rate compared to the PPOS protocol, particularly in younger women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PURPOSE: To compare the effects of the gonadotrophin-releasing hormone (GnRH) agonist protocol, GnRH antagonist protocol, progestin-primed ovarian stimulation (PPOS) protocol, and mild stimulation/natural cycle protocol on the cumulative live birth rate (CLBR) in patients with adenomyosis and Poseidon group 3/4. METHODS: A total of 1090 patients diagnosed with adenomyosis and Poseidon groups 3/4 group who underwent in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) from January 2013 to December 2020 were included. Demographic characteristics, laboratory indicators, and clinical outcomes of the four ovarian stimulation protocols were compared. The primary outcome was the CLBR, with binary logistic regression analysis used to explore the factors influencing CLBR. RESULTS: Among the patients with adenomyosis and Poseidon groups 3/4, the CLBR in GnRH agonist protocol group was higher than that in PPOS protocol group (45.78% vs. 22.33%, P = 0.005). Binary logistic regression analysis revealed that GnRH agonist protocol had a higher CLBR compared to PPOS protocol (adjusted odds ratio (aOR) 3.26, 95% confidence interval (CI): 1.56-6.83, P = 0.002), while no significant differences were found when comparing PPOS protocol with GnRH antagonist protocol (P = 0.093) and mild stimulation/natural cycle protocol (P = 0.125). In the  0.05). CONCLUSION: For patients with both adenomyosis and Poseidon groups 3/4, GnRH agonist protocol showed a higher CLBR, especially in patients < 35 years (Poseidon group 3).

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: pmc

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-06-04T00:31:34.272086+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine